Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

Gemcitabine 3Cisplatin 2paricalcitol 1Taxes 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Resectable Pancreatic Cancer × Gemcitabine × Clear all
NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT02047513 2023-06-15

NEONAX

AIO-Studien-gGmbH

Phase 2 Completed
127 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

NCT03392571 2019-05-07

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Pancreatic Cancer Research Team

Phase 2 Withdrawn
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡